Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism

Hypertension Research volume 44, pages 426–434 (2021)Cite this article

Abstract

Patients with primary aldosteronism (PA) have a high prevalence of microalbuminuria (MAU), which leads to more severe systemic vascular damage. However, the primary recommended drug treatment for PA, spironolactone (SPL), has had poor patient compliance owing to its adverse effects, and the effect of SPL compliance on MAU has not been fully evaluated in patients with PA. We analyzed the effect of SPL compliance on endothelial dysfunction by assessing MAU in patients with PA. The study included 145 confirmed PA patients who received long-term medical treatment (mean, 5 years). As expected, compliance with SPL treatment improved patients’ blood pressure and serum potassium levels. Patients with PA who complied fully with SPL treatment had a lower rate of MAU than noncompliant patients (13.73% versus 34.88%, respectively; P = 0.004). Multivariate logistic regression analyses adjusted for age and sex showed that continuous SPL treatment was associated with a lower presence of MAU (odds ratio, 0.319; 95% confidence interval, 0.135–0.750; P = 0.009). This association remained significant after further adjusting for other major risk factors. However, in the subgroup analysis, the protective effect against MAU was limited in compliant patients treated with ≥40 mg/day SPL compared with noncompliant patients (9.62% versus 34.88%, respectively; P < 0.05). Our findings demonstrated that in addition to improving high blood pressure and hypokalemia, full compliance with the appropriate dose of SPL may benefit endothelial function, as reflected by a lower prevalence of MAU in patients with PA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Funder JW. Primary aldosteronism: present and future. Vitam Horm 2019;109:285–302.

    Article  CAS  Google Scholar 

  2. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016;101:1889–916.

    Article  CAS  Google Scholar 

  3. Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017;69:1811–20.

    Article  Google Scholar 

  4. Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41–50.

    Article  CAS  Google Scholar 

  5. Thum T, Schmitter K, Fleissner F, Wiebking V, Dietrich B, Widder JD, et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 2011;32:1275–86.

    Article  CAS  Google Scholar 

  6. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006;48:165–71.

    Article  CAS  Google Scholar 

  7. Vita JA. Endothelial function. Circulation 2011;124:e906–12.

    Article  Google Scholar 

  8. Liu G, Yin GS, Tang JY, Ma DJ, Ru J, Huang XH. Endothelial dysfunction in patients with primary aldosteronism: a biomarker of target organ damage. J Hum Hypertens 2014;28:711–5.

    Article  CAS  Google Scholar 

  9. Deckert BF-R T, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. Diabetologia 1989;32:219–26.

    Article  Google Scholar 

  10. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006;48:232–8.

    Article  CAS  Google Scholar 

  11. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 2006;17:2106–11.

    Article  CAS  Google Scholar 

  12. Wang AMATJ. Evaluating the role of biomarkers for cardiovascular risk prediction: focus on CRP, BNP and urinary microalbumin. Expert Rev Mol Diagn 2007;7:793–804.

    Article  CAS  Google Scholar 

  13. Karashima S, Yoneda T, Kometani M, Ohe M, Mori S, Sawamura T, et al. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism. Hypertens Res 2016;39:133–7.

    Article  CAS  Google Scholar 

  14. Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, et al. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism. Eur J Endocrinol 2013;168:75–81.

    Article  CAS  Google Scholar 

  15. Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, et al. Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab 2014;99:1593–8.

    Article  CAS  Google Scholar 

  16. Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 2012;29:e184–190.

    Article  CAS  Google Scholar 

  17. Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications 2008;22:303–8.

    Article  Google Scholar 

  18. Hwang YC, Yoon KH, Cha BS, et al. Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. Int J Clin Pract 2017;71:1–8.

    Article  Google Scholar 

  19. Luo Q, Li NF, Yao XG, Zhang DL, Abulikemu SF, Chang GJ, et al. Potential effects of age on screening for primary aldosteronism. J Hum Hypertens 2016;30:53–61.

    Article  Google Scholar 

  20. Luo Q, Li N, Wang M, Yao X, Heizhati M, Zhang D, et al. Mild primary aldosteronism (PA) followed by overt PA are possibly the most common forms of low renin hypertension: a single-center retrospective study. J Hum Hypertens 2019; https://doi.org/10.1038/s41371-019-0291-y.

  21. Tuersun T, Luo Q, Zhang Z, Wang G, Zhang D, Wang M, et al. Abdominal aortic calcification is more severe in unilateral primary aldosteronism patients and is associated with elevated aldosterone and parathyroid hormone levels. Hypertens Res 2020; https://doi.org/10.1038/s41440-020-0529-7.

  22. Chinese Hypertension League CSoC, Hypertension Committee of the Chinese Medical Doctor Association,et al. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol. 2018;16:182–241.

  23. Miller BS, Turcu AF, Nanba AT, Hughes DT, Cohen MS, Gauger PG, et al. Refining the definitions of biochemical and clinical cure for primary aldosteronism using the primary aldosteronism surgical outcome (PASO) classification system. World J Surg 2018;42:453–63.

    Article  CAS  Google Scholar 

  24. Ukena C, Mahfoud F, Kindermann M, Graber S, Kindermann I, Schneider M, et al. Smoking is associated with a high prevalence of microalbuminuria in hypertensive high-risk patients: data from I-SEARCH. Clin Res Cardiol 2010;99:825–32.

    Article  CAS  Google Scholar 

  25. Hao G, Wang Z, Zhang L, Chen Z, Wang X, Guo M, et al. Prevalence of microalbuminuria among middle-aged population of China. Angiology 2013;66:49–56.

    Article  Google Scholar 

  26. Catena C, Colussi G, Martinis F, Novello M, Sechi LA. Microalbuminuria and plasma aldosterone levels in nondiabetic treatment-naive patients with hypertension. J Hypertens 2017;35:2510–6.

    Article  CAS  Google Scholar 

  27. da Costa PM, Cortez AF, de Souza F, Mares GS, Dos Santos BDM, Muxfeldt ES. Prognostic impact of baseline urinary albumin excretion rate in patients with resistant hypertension: a prospective cohort study. J Hum Hypertens 2018;32:139–49.

    Article  Google Scholar 

  28. Ota H, Takehara N, Aonuma T, et al. Association between microalbuminuria predicting in-stent restenosis after myocardial infarction and cellular senescence of endothelial progenitor cells. PLoS ONE 2015;10:1–13.

    Google Scholar 

  29. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198–202.

    Article  CAS  Google Scholar 

  30. Selvaraj S, Claggett B, Shah SJ, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail 2018;11:1–10.

    Article  Google Scholar 

  31. Chinese Society of Endocrinology Adrenal Group.Expert consensus on the diagnosis and treatment of primary aldosteronism.Chin J Endocrinol Metab, 2016;32:188–95.

  32. Satoh M, Maruhashi T, Yoshida Y, Shibata H Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism. Hypertens Res. 2019; https://doi.org/10.1038/s41440-019-0244-4.

  33. Persson F, Lindhardt M, Rossing P, et al. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review. J Renin Angiotensin Aldosterone Syst 2016;17:1–10.

    Article  CAS  Google Scholar 

  34. Chen Y, Liu P, Chen X, Li Y, Zhang F, Wang Y. Effects of different doses of irbesartan combined with spironolactone on urinary albumin excretion rate in elderly patients with early type 2 diabetic nephropathy. Am J Med Sci 2018;355:418–24.

    Article  Google Scholar 

  35. Lechner B, Lechner K, Heinrich D, Adolf C, Holler F, Schneider H, et al. Therapy of endocrine disease: medical treatment of primary aldosteronism. Eur J Endocrinol 2019;181:R147–53.

    Article  CAS  Google Scholar 

  36. Gregory LHundemerM,MPH, Gary CCurhan,MD,SCD, Nicholas Yozamp,MD, et al. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMACardiology 2018;3:768–74.

    Google Scholar 

  37. X Jeunemaitre, G Chatellier, C Kreft-Jais, A Charru, C DeVries, PF Plouin. et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820–5.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by the “Nonprofit Central Research Institute Fund of the Chinese Academy of Medical Sciences” [2019PT330003].

Author information

Author notes

  1. These authors contributed equally and share first authorship: Xiaotong Wang, Qin Luo.

Authors and Affiliations

  1. Hypertension Center of People’s Hospital of Xinjiang Uygur Autonomous Region; Xinjiang Hypertension Institute, National Health Committee Key Laboratory of Hypertension Clinical Research, Urumqi, 830001, Xinjiang, China

    Xiaotong Wang, Qin Luo, Menghui Wang, Junli Hu, Delian Zhang, Weiwei Zhang, Guoliang Wang & Nanfang Li

Authors
  1. Xiaotong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qin Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Menghui Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junli Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Delian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weiwei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guoliang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nanfang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nanfang Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Luo, Q., Wang, M. et al. Long-term impact of spironolactone compliance on microalbuminuria in patients with primary aldosteronism. Hypertens Res 44, 426–434 (2021). https://doi.org/10.1038/s41440-020-00589-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-020-00589-8

Keywords

This article is cited by

Search

Advanced search

Quick links